Skip to main content

Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

CBE ID
0377
1.4 Project
Cancer
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Full Year 2015
Is Under Review
No
1.3 Measure Description

Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) or an acute leukemia who had baseline cytogenetic testing performed on bone marrow

    • 1.14 Numerator

      Patients who had baseline cytogenetic testing performed on bone marrow

    • 1.15 Denominator

      All patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) or an acute leukemia

    • Exclusions

      Documentation of medical reason(s) for not performing baseline cytogenetic testing on bone marrow (eg, no liquid bone marrow or fibrotic marrow)

      Documentation of patient reason(s) for not performing baseline cytogenetic testing on bone marrow (eg, at time of diagnosis receiving palliative care or not receiving treatment as defined above)

      Documentation of system reason(s) for not performing baseline cytogenetic testing on bone marrow (eg, patient previously treated by another physician at the time cytogenetic testing performed)

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cancer Project 2015-2016
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      American Society of Hematology
      Steward Organization POC Email
      [email protected]
      Steward Organization Copyright

      The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

      The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

      Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA) or the American Society of Hematology (ASH). Neither ASH, nor the AMA, nor the AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.

      The AMA and ASH encourage use of the Measures by other health care professionals, where appropriate.

      THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

      © 2015 American Medical Association and American Society of Hematology. All Rights Reserved.

      Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASH, the AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

      CPT® contained in the Measures specifications is copyright 2004-2015 American Medical Association. LOINC® copyright 2004-2015 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2015 The International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2015 World Health Organization. All Rights Reserved.